PTPRF
PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Overview
Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Erlotinib Hydrochloride.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
- 1 · What it is
PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity.
- 3 · How drugs use it
No product in this corpus aims at PTPRF yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9670 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P10586 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRF (2 evidence items, 0 assertions, 1 variants; diseases: Lung Non-small Cell Carcinoma (GraphQL API, CC0))
Biology
Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Location: Membrane (UniProt). Locus 1p34.2 (HGNC).
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PTPRF" OR ABSTRACT:"PTPRF" OR TITLE:"protein tyrosine phosphatase receptor type F" OR ABSTRACT:"protein tyrosine phosphatase receptor type F" OR TITLE:"Receptor-type tyrosine-protein phosphatase F" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase F") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRF, not a curated reading list.